Sunday, December 02, 2018 1:47:50 PM
This is a wonderful board for collective effort, thanks to all who contribute. I have tried to organize this post as well as I could, suggestions and corrections are welcome.
Company website - upcoming and past events:
https://www.anavex.com/investor-material/events/
Company Website - presentations on line:
https://www.anavex.com/investor-material/
_________________________________________________________________________________________________________________________
NEW NEWS:
Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers
https://www.anavex.com/anavex-life-sciences-announces-fda-approval-of-ind-for-phase-2-trial-of-anavex2-73-in-patients-with-rett-syndrome/
Additional recent discussion under Rett Syndrome headline..
_________________________________________________________________________________________________________________________UPCOMING PRESENTATIONS AND OTHER POSSIBLE EVENTS:
Dec. 11 NYAS symposium, Alzheimer’s Disease Therapeutics: Alternatives to Amyloid, that Nell Rebowe is organizing with Dr. Rudy Tanzi and Dr. Howard Fillit of the Alzheimers's Drug Discovery Foundation.
https://www.nyas.org/events/2018/alzheimer-s-disease-therapeutics-alternatives-to-amyloid/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143979620
Pertinent comments on the above from TTAV: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144635533
Daniel Klamer will present a webinar, Precision Medicine in CNS Drug Development, on December 13th:
https://resources.sharevault.com/webinar_precision-medicine-in-cns-drug-development (Thanks TTav)
February 19-21, 2019, Anavex will be participating in the 7th World CNS Summit - Targeting Neurodegenerative Diseases.
https://www.nyas.org/events/2018/alzheimer-s-disease-therapeutics-alternatives-to-amyloid/?tab=agenda
From the event’s description:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144414392
_________________________________________________________________________________________________________________________
Hampel Speaks!:
Harald Hampel may be the world's foremost authority on Alzheimer's. It is an honor to have him speak on behalf of Anavex.
https://www.alzforum.org/member-directory/harald-hampel-0
AAIC August 2018
htps://investorshub.advfn.com/boards/read_msg.aspx?message_id=142864055
(video and ad hoc transcript above)
Slides: https://www.anavex.com/wp-content/uploads/2018/07/Anavex-AAIC-2018-DT-01-Presentation.pdf
On Nov 10th, 16th Asian Oceanian Congress of Neurology (AOCN) - Coex, Seoul Korea -
Keynote presentation: Precision Medicine for Neurodegenerative Diseases- Harald Hampel
https://www.youtube.com/watch?v=olaYKyue1HM
Hampel at the VI International Congress on Research and Innovation in Neurodegenerative Diseases:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143924640
Comments on the above: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921147
Hampel's new web site on precision medicine features his presentation on 2-73.
https://www.apmiscience.com/interviews
_________________________________________________________________________________________________________________________
PRESS AND THIRD PARTY COVERAGE:
Anavex and Ariana (thanks TTAV66)
"Ariana Pharma promoting their work with Anavex. Nice write up, including the further reading section where they point to the upcoming CTAD presentation and detail their full history of collaboration with Anavex. "
http://www.arianapharma.com/2018/09/alzheimer-precision-medicine/
Another article by Ariana Pharma on their website, this time highlighting the CTAD presentation:
http://www.arianapharma.com/2018/10/arianas-ai-demonstrate-clinical-efficacy-of-anavex2-73-for-alzheimers-patient-ctad-2018/
Thanks to polarbear for this link.. all I can say is "It's about time"...
https://alzheimersnewstoday.com/2018/10/31/anavex-2-73-slows-cognitive-decline-alzheimers-extension-study/
Press coverage of AVXL at 2018 CTAD:
http://cnafinance.com/anavex-life-sciences-avxl-stock-gaining-on-clinical-data/20696
http://www.bioworld.com/content/tiny-anavex-thinks-big-three-year-ad-data-ctad
Recent press coverage of the 2-73 Alzheimer's trial in Australia per TTTav66:
https://www.9news.com.au/2018/10/19/18/29/dementia-pill-clinical-trial-anavex-2-73
Australian press covering the 2-73 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772297
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143773822
Apologies and thanks to the poster who first posted this article, having trouble keeping up with the good news:
https://www.yourlifechoices.com.au/health/news/alzheimers-trial-delivers-results
When the hugs and kisses stopped...
https://www.abc.net.au/news/2018-11-14/dementia-onset-when-the-hugs-stopped/10433574
Videos of Australian Patients from the P2a trial
UK press covering the 2-73 trial (repeat of AU coverage):
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772909
From K9uwa aka John: Today in Parkinsons News Today ENROLLING NOW in Spain article.
http://parkinsonsnewstoday.com/2018/11/01/anavex-recruiting-parkinsons-dementia-patients-spain-anavex-2-73-trial/
_________________________________________________________________________________________________________________________
AUDIO PRESENTATIONS:
Cantor Fitzgerald Presentation from Cantor Fitzgerald Global Healthcare Conference October 3, 2018 2:50 p.m.
http://wsw.com/webcast/cantor7/avxl/
Comment on the above from dia76ca "At Cantor Dr. Missing said that the Rett trial would "clear VERY SOON"(At the 27:30 minute mark). We would do well to remember some of the other things he said.(e.g. Cash on hand for 2 years...21:21 minute mark ; Anavex 3-71 in clinic in 2019...29:34 minute mark ; Parkinson read-out in 2019...30:40 minute mark."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144349470
Additional audio presentations on the company web site see links at top of post.
_________________________________________________________________________________________________________________________
VIDEO PRESENTATIONS
Anavex SAB member Dr Paul Aisen speaks about PET Scans:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921781
History of rettsyndrome.org featuring Christopher Missling:
Dr. Tangui Maurice on the Sigma 1 - 2015 video:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143980208
Additional video presentations on the company web site see links at top of post.
_________________________________________________________________________________________________________________________
SLIDE SHOWS AND POSTERS:
From TTTav: October Corporate Presentation used at the Cantor Fitzgerald Conference
https://www.anavex.com/wp-content/uploads/2018/10/Anavex-Presentation-Oct-2018.pdf
Dr Robert Lisak’s MS poster presented at the 2018 ECTRIMS conference:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144223191&txt2find=ectrims
CTAD 2018 slides - see the following grouping
_________________________________________________________________________________________________________________________
OCTOBER 2018 CTAD PRESENTATIONS:
Poster available during the duration of CTAD:
P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the
Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane, MBBS FRANZCP1 , Michael Kornhauser BPharm1 , Ella Modini BSc1 , Harald Hampel, MD PhD2 , Stephan Toutain MS3, Christopher Missling PhD3
Friday, October 26 - Late Breaking Session
3.30 - 3.45 p.m. LB9 - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers
Harald Hampel, MD, PhD1 , Mohammad Afshar, MD, PhD2 , Frédéric Parmentier, PhD2 , Coralie Williams, MSc2 , Adrien Etcheto, MSc2 , Federico Goodsaid, PhD3 , Christopher U Missling, PhD4
****Information on Federico Goodsaid,Regulatory Pathfinders
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143696879
https://www.linkedin.com/in/regulatorypathfinders (Thanks blanka)
Saturday, October 27- Oral communications:
1.30 - 1.45 p.m. OC31 - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation Gustavo A. Jimenez-Maggiora, MBA1 , Rema Raman, PhD1 , Michael S. Rafii, MD, PhD1 , Reisa Anne Sperling, MD2,3, Jeffrey Lee Cummings, MD4, Paul S. Aisen, MD1
Slides from 2018 CTAD:
https://www.anavex.com/wp-content/uploads/2018/10/ANAVEX2-73_CTAD_2018_Presentation.pdf
Slide 16 shows good response in those with ApoE4 variant even though it is expected to be associated with faster rate of AD progression:
https://www.nature.com/articles/tpj200958
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144500445
Investor2014 on CTAD slides
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495242
CTAD overviews:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144493744
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495242
Some CTAD coverage:
_________________________________________________________________________________________________________________________
TRIAL PROCEDURE AND PROTOCOLS:
Arguments for accelerated approval for 2-73.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143620275
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143624077
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144651100
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144731123
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144982778
Provisional approval in Australia may not require completion of the P3.. (links thanks to JonJones325)
https://www.tga.gov.au/publication/provisional-determination-eligibility-criteria
https://www.tga.gov.au/publication/provisional-determination
https://www.tga.gov.au/presentation-provisional-approval-pathway-prescription-medicines
Definition of Major Therapeutic Advance in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144734105
Precedents and legal pathways to approval from Biostockclub & Nidan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205166
Link from the above post naming precedents for drug approval without a Random Controlled Trial:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932294/#!po=95.1923
On ACTC participation in the U.S.:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144487503
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145208260
New guidance for early stage Alzheimer's being developed in the U.S.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205259
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145208035
Current state of Alzheimer's fluid biomarkers. - Full Paper (from Investor2014)
https://link.springer.com/article/10.1007/s00401-018-1932-x
What is a Special Protocol Assessment?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140087471
Precision Medicine and “The Economics of Drug Development”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144010889
How enrollment works:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144955802
The company's stated timeline for Alzheimer's P2b/3:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144956279
Missling states that PET scans will be used in P2/3 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143981335
On dosage of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144631198
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495639
Discussion of P2a trial dropouts:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144496759
_________________________________________________________________________________________________________________________
ALZHEIMER'S TRIAL DISCUSSIONS AND UPDATES:
https://www.slideshare.net/TherapeuticGoodsAdministration/clinical-trials-tga-role
What does Donepezil do?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144744473
On the difficulty in diagnosing Alzheimer's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145129244
French healthcare system decides it will no longer reimburse for Donepezil and other Alzheimer's drugs.
http://english.prescrire.org/en/81/168/55126/0/NewsDetails.aspx
How the U.S. is failing its people in healthcare:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145076878
Alzheimer's & SOC - too many patients exposed to drug interactions: French data:
http://english.prescrire.org/en/81/168/49338/0/NewsDetails.aspx
Basic biology concepts for Alzheimer’s disease
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137348423
Alzheimer's and Sleep:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134772774
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134771894
Falconer posts on sleep and Alzheimer's :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144599308
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135780296
(see also insomnia patent under IP)
Doc328 on Alzheimer's vaccines:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145066297
November 2018 publication on Sigma 1 - note the dates of publication history starting in 2016:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771390/pdf/CN-16-97.pdf
Comordbidity in Alzheimer's and dementia from nidan7500
https://alzheimersnewstoday.com/2018/11/14/comorbidities-common-disabling-in-alzheimers-and-dementia-patients-uk-study-finds/
More on comorbidity:
http://dare.ubvu.vu.nl/bitstream/handle/1871/15970/7839.pdf?sequence=5#page=77
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417646/
https://academic.oup.com/ageing/advance-article/doi/10.1093/ageing/afy155/5133260
Of Mice and Men - Alzheimer's drug development through the years:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143978495
See also CTAD 2018 discussions in group above.
_________________________________________________________________________________________________________________________
PARKINSON'S DEMENTIA TRIAL DISCUSSIONS AND UPDATES:
How the Parkinson's Dementia trial may help expedite Alzheimer's approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143580569
Biostockclub on Parkinson's dosage:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144533102
Parkinson's News Today announces trial with participation of MJF foundation from whippensaw:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144653898
EU Parkinson's trail info:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144654071
Spanish trial info:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144654240
_________________________________________________________________________________________________________________________
RETT SYNDROME TRIAL DISCUSSIONS AND UPDATES:
Rett Syndrome trial and endpoints announced on Clinicaltrials.gov 11/29/18 (Thanks to poster Abel and Cabel)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145164109
Info on Dr. Kaufmann who will be running the 2-73 Rett Syndrome trial:
http://gcbcenter.kennedykrieger.org/staff.jsp
Rett Syndrome in adults:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145216562
Rett Syndrome & Fragile x - they are are related:
From Talon38 (post 173314) "NIH's updated (2 days ago) information on Fragile X. Notice both the similarities and differences (predominantly a male diseases). Fragile X is one of 2-73's pipeline targets as is Infantile Spasms and Angelman's. Not a stretch to believe that Tayo Fadiran has been working CDER and NIH for a combined clinical trial approach to these orphan diseases. With positive Rett Syndrome results, that may come to fruition. The 2-73 "train" is gathering momentum!"
https://ghr.nlm.nih.gov/condition/fragile-x-syndrome
Investor2014 reminds us of the Rett Syndrome Study Design:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144701675
Discussion of Rett Trial Design why it is structured the way it is:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144356675
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205166
On the phases of Rett Syndrome:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144701046
Will the trial be moved to Australia?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144362026
On Rett Syndrome and the M4 Receptor from Investor2014:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144347886
Other Rett Syndrome related posts:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144357506
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135703149
Talon38 provided this NIH link on Rett Syndrome:
https://ghr.nlm.nih.gov/condition/rett-syndrome
dadofmarcmax on Rett Syndrome and other epileptic diseases:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144438361
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135019599
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135028269
Paper on Rett Syndrome treatment procedures:
https://pdfs.semanticscholar.org/c2c8/1063888a7aecffd3b1fe74a7b67496b2554f.pdf
The significance of Dr Andrew Cole MD authority on Epilepsy to Anavex SAB:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144358640
PennyDouble reminds us, we have an expert on the SAB :
https://www.anavex.com/anavex-life-sciences-appoints-distinguished-researcher-neurology-epilepsy-scientific-advisory-board/
_________________________________________________________________________________________________________________________
GUT and BRAIN:
HOMEOSTATIC NETWORKING: THE ROLE OF PHYTOCHEMISTRY, THE ENDOCANNABINOID SYSTEM AND POTENTIAL FUTURE THERAPEUTICS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144438361
Restoration of gut microbiota as MOA in a possibly competitive Chinese compound:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144442713
XenaLives posts on gut/brain:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144443836
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144443854
_________________________________________________________________________________________________________________________[color=red]OTHER CNS ADDITIONAL INDICATIONS:
From dadofmarcmax, the linked site has TONS of info:
"Why does Anavex 2-73 have effects on seemingly different neuro-degenerative disorders? What makes it so special? "
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143816865
Fragile X is a growing concern (link from cninc):
https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00564/full
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144971728
dadofmarcmax on treatment of epilepsy with Anavex platform drugs:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=127872231
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131111781
Anavex also has Orphan Drug Designation for Infantile Spasms:
https://www.anavex.com/anavex-announces-u-s-fda-orphan-drug-designation-for-anavex-2-73-for-treatment-of-infantile-spasms/
_________________________________________________________________________________________________________________________[color=red]GENERAL MISC. DISCUSSIONS AND UPDATES:
An excellent summary of why we are here from poster sokol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143320176
Sokol on Anavex's international strategies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144504285
Link to PeterKarol's blog:
https://piotrpeterblog.com/
Short term milestone summary:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144330988
CRISPER discovery of likely MOA for 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144274561
Missling has a strategy - comments from posters on that strategy:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144051610
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144350599
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145164402
November 2018 - New SAB member Dr. Dag Aarsland, support for current and future pipeline:
https://globenewswire.com/news-release/2018/11/08/1647793/0/en/Anavex-Life-Sciences-Strengthens-its-Scientific-Advisory-Board-with-Distinguished-Researcher-for-Clinical-Treatment-of-Parkinson-s-Disease-Dementia-PDD.html
Charts showing periods of institutional accumulation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144037184
Dangerous medicines and mitochondrial dysfunction:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142393634&txt2find=mitochondrial
Personal comments from falconer66a on the failure of traditional western medicine:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144979916
On Sleep:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135735670
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144599308
Perspective on how quickly Anavex could morph into a profitable entity , making further dilution unnecessary. This may provide urgency for institutions to establish a position where stock has limited liquidity resulting in a pre-approval ramp up of pricing.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143560772
AVXL 2-73 and cerebral blood flow:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143582952
Brain cells from stem cells at Lund University:
https://www.lunduniversity.lu.se/article/new-method-grows-brain-cells-from-stem-cells-quickly-and-efficiently
Dr. Tanzi on infection and Alzheimer's, also "soda brain".
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143979877
Sokol with a 2016 perspective on potential Alzheimer's treatments:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144809093
b]Shareholder meeting report:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140128467&txt2find=shareholder|meeting
_________________________________________________________________________________________________________________________
Anavex IP protection:
Patent for Insomnia: (EN) A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY, AND AGITATION
Abstract:
(EN)A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10mg to about 50mg, with particular reference to about 20 to 30mg. (from basparks79)
https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=173B4DDABFF25B0C26F75F5B8E98D703.wapp2nA?docId=WO2018022848&recNum=1&maxRec=13&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&tab=PCT+Biblio
More on the patent for Insomnia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144833903
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144834373
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144842204
_________________________________________________________________________________________________________________________
GENERAL INFO ON TRIAL PROCEDURE AND FDA:
Check this out on retrospective validation: (from Nidan7500)
https://www.nature.com/articles/6500363#hypothetical-safety-example-seeking-drug-approval-in-the-dnasubgroup-of-patients-with-less-risk-of-a-cardiovascular-adverse-events-after-trial-completion
What’s in a p value? - a significant read! (from Investor2014)
http://www.evaluate.com/vantage/articles/analysis/vantage-views/whats-p-value
_________________________________________________________________________________________________________________________
Big Pharma, BIIB AND POTENTIAL PARTNER DISCUSSION:
Did BIIB blink?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143525102
BIIB's problem with Alzheimer's trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144801572
Bayer also bailing on R&D:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145174145
Why did Big Pharma bail on Alzheimer's trials early 2018? Possible Answer:
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM596728.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205259
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145214094
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145215823
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145214295
Anavex - Biogen & MS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135630393
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143729928
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143732818
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143734046
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144040837
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM